E- and A-type cyclins as markers for cancer diagnosis and prognosis

Expert Review of Molecular Diagnostics

Volumn 3, Issue 5, 2003, Pages 617-633

  Yasmeen, Amber ^a   Berdel, Wolfgang E ^a   Serve, Hubert ^a   Müller Tidow, Carsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast cancer; Cancer; CDK2; Cell cycle; CKIs; Cyclin; Cyclin A; Cyclin A1; Cyclin E; Cyclin E2; Cyclin dependent kinase

Indexed keywords

ANKYRIN; CYCLIN A; CYCLIN A1; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLIN E2; CYCLINE; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DIAGNOSTIC PROCEDURE; DNA REPLICATION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN GENOME; PATHOGENESIS; PROGNOSIS; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION;

CELL CYCLE; CYCLIN A; CYCLIN E; HUMANS; NEOPLASMS; PROGNOSIS; RETINOBLASTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 0041319434     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.5.617     Document Type: Review

References (230)

1. Morgan DO, Principles of CDK regulation. Nature 374(6518), 131-134 (1995).
2. Sherr CJ. The pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60(14), 3689-3695 (2000). Comprehensive review which describes the role of cancer cell cycle and deregulation of different pathways.
3. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308(Pt 3), 697-711 (1995).
4. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 133(2), 389-396 (1983).
5. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13(12), 1501-1512 (1999).
6. Lee SJ, Park MT. Cell cycle and cancer. J. Biochem. Mol. Biol. 36(1), 60-65 (2003).
7. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9(10), 1149-1163 (1995).
8. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86(3), 841-854 (1995).
9. Weinstein IB, Begemann M, Zhou P et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3(12 Pt 2), 2696-2702 (1997).
10. Han EK, Lim JT, Arber N et al. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35(2), 95-101 (1998).
11. Sgambato A, Flamini G, Cittadini A, Weinstein IB. Abnormalities in cell cycle control in cancer and their clinical implications. Tumori 84(4), 421-433 (1998).
12. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347(20), 1566-1575 (2002). Further establishes the prognostic importance of cyclin E in breast cancer.
13. Muller-Tidow C, Metzger R, Kugler K et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61(2), 647-653 (2001).
14. Bukholm IR, Bukholm G, Nesland JM. Overexpression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int. J. Cancer 93(2), 283-287 (2001).
15. Muller-Tidow C, Diederichs S, Schrader MG et al. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett. 190(1), 89-95 (2003).
16. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2(2), 103-112 (2002).
17. Rocco JW, Sidransky D. P16 (MTS-1/CDKN2/INK4A) in cancer progression. Exp. Cell. Res. 264(1), 42-55 (2001).
18. Nguyen TT, Mohrbacher AF, Tsai YC et al. Quantitative measure of c-ABL and p 15 methylation in chronic myelogenous leukemia: biological implications. Blood 95(9), 2990-2992 (2000).
19. kip1 protein: prognostic implications in primary breast cancer. Nature Med. 3(2), 227-230 (1997).
20. Esposito V, Baldi A, DeLuca A et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57(16), 3381-3385 (1997).
21. Mori M, Mimori K, Shiraishi T et al. P27 expression and gastric carcinoma. Nature Med. 3(6), 593 (1997).
22. Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3(2), 231-234 (1997).
23. kip1 and cyclin E in breast cancer.
24. kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl Cancer Inst. 90(17), 1284-1291 (1998).
25. Florenes VA, Maelandsmo GM, Kerbel RS et al. Protein expression of the cell-cycle inhibitor p27kip1 in malignant melanoma: inverse correlation with disease-free survival. Am. J. Pathol. 153(1), 305-312 (1998).
26. Pines J, Hunt T. Molecular cloning and characterization of the mRNA for cyclin from sea urchin eggs. EMBO J. 6(10), 2987-2995 (1987).
27. Swenson KI, Farrell KM, Ruderman JV. The clam embryo protein cyclin A induces entry into M phase and the resumption of meiosis in xenopus oocytes. Cell 47(6), 861-870 (1986).
28. Sherr CJ. Mammalian G1 cyclins. Cell 73(6), 1059-1065 (1993).
29. Pines J. Cell cycle: confirmational change. Nature 376(6538), 294-295 (1995).
30. Reed SI. Control of the GIS transition. Cancer Surv. 29, 7-23 (1997).
31. Sherr CJ. G1 phase progression: cycling on cue. Cell 79(4), 551-555 (1994).
32. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257(5078), 1958-1961 (1992).
33. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259(5103), 1908-1912 (1993).
34. Koff A, Cross F, Fisher A et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66(6), 1217-1228 (1991).
35. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast. Cell 66(6), 1197-1206 (1991).
36. Damjanov I, Shan J, Wang RF, Damjanov A, DeLoia JA. Molecular cloning and characterization of murine cyclin E. Biochem. Biophys. Res. Commun. 201(2), 994-1000 (1994).
37. Botz J, Zerfass-Thome K, Spitkovsky D et al. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol. Cell Biol. 16(7), 3401-3409 (1996).
38. Moore JD, Yang J, Truant R, Kornbluth S. Nuclear import of CDK/cyclin complexes: identification of distinct mechanisms for import of CDK2/cyclin E and CDC2/cyclin B1. J. Cell Biol. 144(2), 213-224 (1999).
39. Jackman M, Kubota Y, den Elzen N, Hagting A, Pines J. Cyclin A- and cyclin E-CDK complexes shuttle between the nucleus and the cytoplasm. Mol. Biol. Cell 13(3), 1030-1045 (2002).
40. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J. 13(8), 773-780 (1999). Provides an overview of the cyclin E involvement in different cancers.
41. Geng Y, Eaton EN, Picon M et al. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12(6), 1173-1180 (1996).
42. Le Cam L, Polanowska J, Fabbrizio E et al. Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. EMBO J. 18(7), 1878-1890 (1999).
43. Zariwala M, Liu J, Xiong Y. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. Oncogene 17(21), 2787-2798 (1998).
44. Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res. 28(23), E101 (2000).
45. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 60(2), 481-489 (2000).
46. Sewing A, Ronicke V, Burger C, Funk M, Muller R. Alternative splicing of human cyclin E. J. Cell Sci. 107(Pt 2), 581-588 (1994).
47. Mumberg D, Wick M, Burger C et al. Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation. Nucleic Acids Res. 25(11), 2098-2105 (1997).
48. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 11(5), 941-950 (1995).
49. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell Biol. 15(5), 2612-2624 (1995).
50. Porter DC, Zhang N, Danes C et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol. Cell Biol. 21(18), 6254-6269 (2001). Describes hyperactive lower molecular weight forms of cyclin E that are oncogenic.
51. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl Acad. Sci. USA 92(26), 12146-12150 (1995).
52. Polanowska J, Fabbrizio E, Le Cam L et al. The periodic downregulation of cyclin E gene expression from exit of mitosis to end of G(1) is controlled by a deacetylase- and E2F-associated bipartite repressor element. Oncogene 20(31), 4115-4127 (2001).
53. Harper JW, Elledge SJ. CDK inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6(1), 56-64 (1996).
54. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/cip and ink4 CDK inhibitors co-operate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9(15), 1831-1845 (1995).
55. Vogt B, Zerfass-Thome K, Schulze A et al. Regulation of cyclin E gene expression by the human papilloma virus Type 16 E7 oncoprotein. J. Gen. Virol. 80(Pt 8), 2103-2113 (1999).
56. Zerfass K, Schulze A, Spitkovsky D et al. Sequential activation of cyclin E and cyclin A gene expression by human papilloma virus Type 16 E7 through sequences necessary for transformation. J. Virol. 69(10), 6389-6399 (1995).
57. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 224(1), 150-160 (1996).
58. Jones DL, Alani RM, Munger K. The human papilloma virus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of CDK2. Genes Dev. 11(16), 2101-2111 (1997).
59. Mazumder S, Gong B, Almasan A. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells. Oncogene 19(24), 2828-2835 (2000).
60. Jiang W, Wells NJ, Hunter T. Multistep regulation of DNA replication by CDK phosphorylation of hsCDC6. Proc. Natl Acad. Sci. USA 96(11), 6193-6198 (1999).
61. Furstenthal L, Kaiser BK, Swanson C, Jackson PK. Cyclin E uses CDC6 as a chromatin-associated receptor required for DNA replication. J. Cell Biol. 152(6), 1267-1278 (2001).
62. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25a by a CDK2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13(18), 4302-4310 (1994).
63. Jinno S, Suto K, Nagata A et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13(7), 1549-1556 (1994).
64. Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev. 12(4), 456-461 (1998).
65. Ma T, Van Sine BA, Wei Y et al. Cell cycle-regulated phosphorylation of p220 (NPAT) by cyclin L/CDK2 in cajal bodies promotes histone gene transcription. Genes Dev. 14(18), 2298-2313 (2000).
66. Seghezzi W, Chua K, Shanahan F et al. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol. Cell Biol. 18(8), 4526-4536 (1998).
67. Shanahan F, Seghezzi W, Parry D, Mahony D, Lees E. Cyclin E associates with BAF155 and BRG1, components of the mammalian swi-snf complex, and alters the ability of BRG 1 to induce growth arrest. Mol. Cell Biol. 19(2), 1460-1469 (1999).
68. Mussman JG, Horn HF, Carroll PE et al. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene 19(13), 1635-1646 (2000).
69. Carroll PE, Okuda M, Horn HF et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or MDM2 overexpression. Oncogene 18(11), 1935-1944 (1999).
70. Matsumoto Y, Hayashi K, Nishida E. Cyclin-dependent kinase 2 (CDK2) is required for centrosome duplication in mammalian cells. Curr. Biol. 9(8), 429-432 (1999).
71. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G. Requirement of CDK2-cyclin E activity for repeated centrosome reproduction in xenopus egg extracts. Science 283(5403), 851-854 (1999).
72. Lacey KR, Jackson PK, Stearns T. Cyclin-dependent kinase control of centrosome duplication. Proc. Natl Acad. Sci. USA 96(6), 2817-2822 (1999).
73. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 401(6750), 297-300 (1999).
74. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the RB/E2F pathway in cell growth control. J. Cell. Physiol. 173(2), 233-236 (1997).
75. Alevizopoulos K, Vlach J, Hennecke S, Amati B. Cyclin E and c-Myc promote cell proliferation in the presence of p16ink4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16(17), 5322-5333 (1997).
76. Perez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/CDK2 kinase involves induction of cyclin E gene transcription and inhibition of p27(kip1) binding to newly formed complexes. Oncogene 14(20), 2373-2381 (1997).
77. Gudas JM, Payton M, Thukral S et al. Cyclin E2, a novel G1 cyclin that binds CDK2 and is aberrantly expressed in hwnan cancers. Mol. Cell Biol. 19(1), 612-622 (1999).
78. Lauper N, Beck AR, Cariou S et al. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene 17(20), 2637-2643 (1998).
79. Payton M, Coats S. Cyclin E2, the cycle continues. Int. J. Biochem. Cell Biol. 34(4), 315-320 (2002). Summarizes the involvement of cyclin E2 in the cell cycle.
80. Geng Y, Yu Q, Whoriskey W et al. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc. Natl Acad. Sci. USA 98(23), 13138-13143 (2001).
81. Cho NH, Kim YT, Kim JW. Correlation between G1 cyclins and HPV in the uterine cervix. Int. J. Gynecol. Pathol. 16(4), 339-347 (1997).
82. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 11(3), 961-971 (1992).
83. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67(6), 1169-1179 (1991).
84. Kobayashi H, Stewart E, Poon R et al. Identification of the domains in cyclin A required for binding to and activation of p34CDC2 and p32CDK2 protein kinase subunits. Mol. Biol. Cell 3(11), 1279-1294 (1992).
85. Elledge SJ, Richman R, Hall FL et al. CDK2 encodes a 33-kDa cyclin Aassociated protein kinase and is expressed before CDC2 in the cell cycle. Proc. Natl Acad. Sci. USA 89(7), 2907-2911 (1992).
86. Hunter T, Pines J. Cyclins and cancer. Cell 66(6), 1071-1074 (1991).
87. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: cyclin A and CDK2 specifically localize at subnuclear sites of DNA replication. Cell 74(6), 979-992 (1993).
88. Katsu Y, Yamashita M, Hirai T et al. Molecular cloning and immunological analysis of goldfish cyclin A during oocyte maturation. Dev. Biol. 170(2), 616-625 (1995).
89. Howe JA, Howell M, Hunt T, Newport JW. Identification of a developmental timer regulating the stability of embryonic cyclin A and a new somatic A-type cyclin at gastrulation. Genes Dev. 9(10), 1164-1176 (1995).
90. Norbury C, Nurse P. Animal cell cycles and their control. Ann. Rev. Biochem. 61, 441-470 (1992).
91. Lewin B. Driving the cell cycle: M phase kinase, its partners and substrates. Cell 61(5), 743-752 (1990).
92. Lehner CF, O'Farrell PH. The roles of drosophila cyclins A and B in mitotic control. Cell 61(3), 535-547 (1990).
93. Kobayashi H, Minshull J, Ford C et al. On the synthesis and destruction of A- and B-type cyclins during oogenesis and meiotic maturation in xenopus laevis. J. Cell Biol. 114(4), 755-765 (1991).
94. Hunt T, Luca FC, Ruderman JV. The requirements for protein synthesis and degradation and the control of destruction of cyclins A and B in the meiotic and mitotic cell cycles of the clam embryo. J. Cell Biol. 116(3), 707-724 (1992).
95. Ueda R, Togashi S, Takahisa M et al. Sensory mother cell division is specifically affected in a cyclin-A mutant of drosophila melanogaster. EMBO J. 11(8), 2935-2939 (1992).
96. Ravnik SE, Wolgemuth DJ. The developmentally restricted pattern of expression in the male germ line of a murine cyclin A, cyclin A2, suggests roles in both mitotic and meiotic cell cycles. Dev. Biol. 173(1), 69-78 (1996).
97. Sweeney C, Murphy M, Kubelka M et al. A distinct cyclin A is expressed in germ cells in the mouse. Development 122(1), 53-64 (1996).
98. Murphy M, Stinnakre MG, Senamaud-Beaufort C et al. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nature Genet. 15(1), 83-86 (1997).
99. Wolgemuth DJ, Laurion E, Lele KM. Regulation of the mitotic and meiotic cell cycles in the male germ line. Recent Prog. Horm. Res. 57, 75-101 (2002). Excellent review providing an overview of differences between the mitotic and meiotic cell cycle.
100. Sherr CJ. Cancer cell cycles. Science 274(5293), 1672-1677 (1996).
101. Huet X, Rech J, Plet X, Rech J, Plet A, Vie A, Blanchard JM. Cyclin A expression is under negative transcriptional control during the cell cycle. Mol. Cell Biol. 16(7), 3789-3798 (1996).
102. Schulze A, Zerfass K, Spitkovsky D et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl Acad. Sci. USA 92(24), 11264-11268 (1995).
103. Zwicker J, Lucibello FC, Wolfraim LA et al. Cell cycle regulation of the cyclin A, CDC25C and CDC2 genes is based on a common mechanism of transcriptional repression. EMBO J. 14(18), 4514-4522 (1995).
104. Zwicker J, Lucibello FC, Jerome V, Brusselbach S, Muller R. CDF-1 mediated repression of cell cycle genes targets a specific subset of transactivators Nucleic Acids Res. 26(4), 4926-4932 (1998).
105. Liu N, Lucibello FC, Zwicker J, Engeland K, Muller R. Cell cycle-regulated repression of B-myb transcription: co-operation of an E2F site with a contiguous corepressor element. Nucleic Acids Res. 24(15), 2905-2910 (1996).
106. Liu N, Lucibello FC, Korner K et al. CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res. 25(24), 4915-4920 (1997).
107. Philips A, Chambeyron S, Lamb N, Vie A, Blanchard JM. CHF: a novel factor binding to cyclin A CHR corepressor element. Oncogene 18(46), 6222-6232 (1999).
108. Zwicker J, Lucibello FC, Jerome V, Brusselbach S, Muller R. CDF-1-mediated repression of cell cycle genes targets a specific subset of transactivators. Nucleic Acids Res. 25(24), 4926-4932 (1997).
109. Liu N, Lucibello FC, Engeland K, Muller R. A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and antirepression by E2F. Oncogene 16(23), 2957-2963 (1998).
110. DeGregori J, Leone G, Ohtani K, Miron A, Nevins JR. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9(23), 2873-2887 (1995).
111. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S-regulatory genes. Mol. Cell Biol. 15(8), 4215-4224 (1995).
112. Desdouets C, Matesic G, Molina CA et al. Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. Mol. Cell Biol. 15(6), 3301-3309 (1995).
113. Zwicker J, Gross C, Lucibello FC et al. Cell cycle regulation of CDC25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. Nucleic Acids Res. 23(19), 3822-3830 (1995).
114. Blanchard JM. Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues. Biochem. Pharmacol. 60(8), 1179-1184 (2000).
115. Kramer A, Carstens CP, Wasserman WW, Fahl WE. CBP/cycA, a CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription, consists of NF-Y and a novel Mr 115,000 subunit. Cancer Res. 57(22), 5117-5121 (1997).
116. Zerfass K, Spitkovsky D, Schulze A et al. Adenovirus E1A activates cyclin A gene transcription in the absence of growth factors through interaction with p 107. J. Virol. 70(4), 2637-2642 (1996).
117. Duro D, Schulze A, Vogt B et al. Activation of cyclin A gene expression by the cyclin encoded by human herpes virus-8. J. Gen. Virol. 80(Pt 3), 549-555 (1999).
118. Schulze A, Mannhardt B, Zerfass-Thome K, Zwerschke W, Jansen-Durr P. Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papilloma virus Type 16. J. Virol. 72(3), 2323-2334 (1998).
119. Philips A, Huet X, Plet A et al. The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogene 16(11), 1373-1381 (1998).
120. Luciani MG, Hutchins JR, Zheleva D, Hupp TR. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J. Mol. Biol. 300(3), 503-518 (2000).
121. Coverley D, Laman H, Laskey RA. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nature Cell Biol. 4(7), 523-528 (2002). Focuses on the regulation of DNA replication by cyclins in mammalian cells.
122. Saville MK, Watson RJ. The cell-cycle regulated transcription factor B-myb is phosphorylated by cyclin A/CDK2 at sites that enhance its transactivation properties. Oncogene 17(21), 2679-2689 (1998).
123. Plet A, Huet X, Algarte M et al. Relief of cyclin A gene transcriptional inhibition during activation of human primary T-lymphocytes via CD2 and CD28 adhesion molecules. Oncogene 14(21), 2575-2583 (1997).
124. Mihaylov IS, Kondo T, Jones L et al. Control of DNA replication and chromosome ploidy by geminin and cyclin A. Mol. Cell Biol. 22(6), 1868-1880 (2002).
125. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and CDK2-cyclin A. Nature Cell Biol. 1(2), 88-93 (1999).
126. Yang R, Moroserti R, Koeffler HP. Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 57(5), 913-920 (1997).
127. Wolgemuth DJ, Rhee K, Wu S, Ravnik SE. Generic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis. Reprod. Fertil. Dev. 7(4), 669-683 (1995).
128. Liu D, Matzuk MM, Sung WK et al. Cyclin A1 is required for meiosis in the male mouse. Nature Genet. 20(4), 377-380 (1998).
129. Liu D, Liao C, Wolgemuth DJ. A role for cyclin A1 in the activation of MPF and G2-M transition during meiosis of male germ cells in mice. Dev. Biol. 224(2), 388-400 (2000).
130. Ravnik SE, Wolgemuth DJ. Regulation of meiosis during mammalian spermatogenesis: the A-type cyclins and their associated cyclin-dependent kinases are differentially expressed in the germ-cell lineage. Dev. Biol. 207(2), 408-418 (1999).
131. Muller C, Yang R, Beck-von-Peccoz L et al. Cloning of the cyclin A1 genomic structure and characterization of the promoter region. GC boxes are essential for cell cycle-regulated transcription of the cyclin A1 gene. J. Biol. Chem. 274(16), 11220-11228 (1999).
132. Vertino PM, Spillare EA, Harris CC, Baylin SB. Altered chromosomal methylation patterns accompany oncogene-induced transformation of human bronchial epithelial cells. Cancer Res. 53(7), 1684-1689 (1993).
133. Kautiainen TL, Jones PA. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J. Biol. Chem. 261(4), 1594-1598 (1986).
134. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. BCL-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82(6), 1820-1828 (1993).
135. Yang R, Muller C, Huynh V et al. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the RB family of proteins. Mol. Cell Biol. 19(3), 2400-2407 (1999).
136. Muller-Tidow C, Wang W, Idos GE et al. Cyclin A1 directly interacts with B-myb and cyclin A1/CDK2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood 97(7), 2091-2097 (2001).
137. Muller C, Yang R, Idos G et al. C-myb transactivates the human cyclin A1 promoter and induces cyclin A1 gene expression. Blood 94(12), 4255-4262 (1999).
138. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markets of tumor proliferation: immunocytochemical studies in breast cancer. Proc. Natl Acad. Sci. USA 92(12), 5386-5390 (1995).
139. Nielsen NH, Arnerlov C, Cajander S, Landberg G. Cyclin E expression and proliferation in breast cancer. Anal. Cell. Pathol. 17(3), 177-188 (1998).
140. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 52(1-3), 17-28 (1998).
141. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer 74(6), 874-880 (1996).
142. Scott KA, Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br. J. Cancer 76(10), 1288-1292 (1997).
143. Kim HK, Park IA, Heo DS et al. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur. J. Surg. Oncol. 27(5), 464-471 (2001).
144. Strohmaier H, Spruck CH, Kaiser P et al. Human F-box protein hCDC4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413(6853), 316-322 (2001).
145. kip1. Mol. Cell 7(3), 639-650 (2001).
146. Wang XD, Rosales JL, Magliocco A, Gnanakumar R, Lee KY. Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. Oncogene 22(5), 769-774 (2003).
147. Herrera RE, Sah VP, Williams BO et al. Altered cell cycle kinetics, gene expression and G1 restriction point regulation in RB-defident fibroblasts. Mol. Cell Biol. 16(5), 2402-2407 (1996).
148. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14(3), 295-304 (1997).
149. Loden M, Stighall M, Nielsen NH et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of generic aberrations and inactivation of the pRB node. Oncogene 21(30), 4680-4690 (2002).
150. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res. Treat. 56(2), 105-112 (1999).
151. Stanta G, Bonin S, Losi L, Eusebi V. Molecular characterization of intraductal breast carcinomas. Virchows Arch. 432(2), 107-111 (1998).
152. Payton M, Scully S, Chung G, Coats S. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene 21(55), 8529-8534 (2002).
153. Brechot C. Oncogenic activation of cyclin A. Curr. Opin. Genet. Dev. 3(1), 11-18 (1993).
154. Collecchi P, Santoni T, Gnesi E et al. Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. Cytometry 42(4), 254-260 (2000).
155. Michalides R, van Tinteren H, Balkenende A et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer 86(3), 402-408 (2002).
156. Garcia P, Cales C. Endoreplication in megakaryoblastic cell lines is accompanied by sustained expression of G1/S cyclins and downregulation of CDC25C. Oncogene 13(4), 695-703 (1996).
157. Scuderi R, Palucka KA, Pokrovskaja K et al. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 87(8), 3360-3367 (1996).
158. Volm M, Koomagi R, Stammler G et al. Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int. J. Cancer 74(5), 508-512 (1997).
159. Iida H, Towatari M, Tanimoto M et al. Overexpression of cyclin E in acute myelogenous leukemia. Blood 90(9), 3707-3713 (1997).
160. Erlanson M, Portin C, Linderholm B et al. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood 92 (3), 770-777 (1998).
161. Wolowiec D, Benchaib M, Pernas P et al. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue. Leukemia 9(8), 1382-1388 (1995).
162. Wolowiec D, Berger F, Ffrench P, Bryon PA, Ffrench M. CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. Leuk. Lymphoma 35(1-2), 147-157 (1999).
163. Ma J, Xu S, Lai Y, Lu Y. The correlation of cyclin A gene expression with drug resistance in adult acute leukemia patients. Zhonghua Xue Ye Xue Za Zhi 23(5), 243-246 (2002).
164. Kramer A, Hochhaus A, Saussele S et al. Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation. Leukemia 12, 893-898 (1998).
165. Yang R, Nakamaki T, Lubbert M et al. Cyclin A1 expression in leukemia and normal hemtopoietic cells. Blood 93(6), 2067-2074 (1999).
166. Muller C, Yang R, Park DJ et al. The aberrant fusion proteins PML-RAR-α and PLZF-RAR-α contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 96(12), 3894-3899 (2000).
167. Liao C, Wang XY, Wei HQ et al. Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc. Natl Acad. Sci. USA 98(12), 6853-6858 (2001).
168. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res. 60(2), 242-244 (2000).
169. Langenfeld J, Lonardo F, Kiyokawa H et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E downregulation. Oncogene 13(9), 1983-1990 (1996).
170. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 59(10), 2470-2476 (1999).
171. Hayashi H, Ogawa N, Ishiwa N et al. High cyclin E and low p27/kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 34(1), 59-65 (2001).
172. Muller-Tidow C, Bornemann C, Diederichs S et al. Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology. FEBS Lett. 490(1-2), 75-78 (2001).
173. Mishina T, Dosaka-Akita H, Hommura F et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin. Cancer Res. 6(1), 11-16 (2000).
174. Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br. J. Cancer 75(12), 1774-1778 (1997).
175. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer 77(4), 663-669 (1998).
176. Sakaguchi T, Watanabe A, Sawada H et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 82(7), 1238-1243 (1998).
177. Morisaki H, Fujimoto A, Ando A et al. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (CDK) inhibitor by cyclin E/CDK2. Biochem. Biophys. Res. Commun. 240(2), 386-390 (1997).
178. Wang A, Yoshimi N, Suzui M et al. Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J. Cancer Res. Clin. Oncol. 122(2), 122-126 (1996).
179. Kitahara K, Yasui W, Kuniyasu H et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int. J. Cancer 62(1), 25-28 (1995).
180. Yasui W, Akama Y, Kuniyasu H et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J. Exp. Ther. Oncol. 1(2), 88-94 (1996).
181. Ohbu M, Kobayashi N, Okayasu I. Expression of cell cycle regulatory proteins in the multistep process of oesophageal card nogenesis: stepwise overexpression of cyclin E and p53, reduction of p21 (waf1/cip1) and dysregulation of cyclin D1 and p27(kip1). Histopathology 39(6), 589-596 (2001).
182. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y. Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum. Pathol. 32(9), 945-953 (2001).
183. Kohzato N, Dong Y, Sui L et al. Overexpression of cyclin E and cyclin-dependent kinase 2 is correlated with development of hepatocellular carcinomas. Hepatol. Res. 21(1), 27-39 (2001).
184. Simone C, Resta N, Bagella L, Giordano A, Guanti G. Cyclin E and chromosome instability in colorectal cancer cell lines. Mol. Pathol. 55(3), 200-203 (2002).
185. Sutter T, Dansranjavin T, Lubinski J et al. Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma. Int. J. Colorectal Dis. 17(6), 374-380 (2002).
186. Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343(6258), 555-557 (1990).
187. Nozoe T, Korenaga D, Futatsugi M et al. Cyclin A expression in superficial squamous cell carcinoma of the esophagus and coexisting infiltrated lymphocyte follicle. Cancer Lett. 188(1-2), 221-229 (2002).
188. Ohashi R, Gao C, Myazaki M et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 21(1B), 657-662 (2001).
189. Li JQ, Miki H, Wu F et al. Cyclin A correlates with carcinogenesis and metastasis and p27(kip1) correlates with lymphatic invasion in colorectal neoplasms. Hum. Pathol. 33(10), 1006-1015 (2002).
190. Mukawa K, Kawa S, Aoki Y, Zhai Y, Nikaido T. Reduced expression of p53 and cyclin A in intraductal mucin-hypersecreting neoplasm of the pancreas compared with usual pancreatic ductal adenocarcinoma. Am. J. Gastroenterol 94(8), 2263-2267 (1999).
191. Chen Q, Zhou H, Guo W et al. Correlation between the expression of cyclin A protein and p53 activity in oral squamous cell carcinomas. Cytobios 106(412), 87-99 (2001).
192. Molendini L, Benassi MS, Magagnoli G et al. Prognostic significance of cyclin expression in human osteosarcoma. Int. J. Oncol. 12(5), 1007-1011 (1998).
193. Murakami-Mori K, Mori S, Nakamura S. Endogenous basic fibroblast growth factor is essential for cyclin E-CDK2 activity in multiple external cytokine-induced proliferation of aids-associated Kaposi's sarcoma cells: dual control of aids-associated Kaposi's sarcoma cell growth and cyclin E-CDK2 activity by endogenous and external signals. J. Immunol. 161(4), 1694-1704 (1998).
194. Huuhtanen RL, Blomqvist CP, Wildund TA et al. Comparison of the ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br. J. Cancer 79(5-6), 945-951 (1999).
195. Paterlini P, Flejou JF, De Mitri MS et al. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. J. Hepatol. 23(1), 47-52 (1995).
196. Huuhtanen RL, Blomqvist CP, Bohling TO et al. Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness. Cancer Res. 59(12), 2885-2890 (1999).
197. Huuhtanen RL, Wildund TA, Blomqvist CP et al. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Br. J. Cancer 81(6), 1017-1021 (1999).
198. Session DR, Lee GS, Choi J, Wolgemuth DJ. Expression of cyclin E in gynecologic malignancies. Gynecol. Oncol. 72(1), 32-37 (1999).
199. Oshita T, Shigemasa K, Nagai N, Ohama K. P27, cyclin E and CDK2 expression in normal and cancerous endometrium. Int. J. Oncol. 21(4), 737-743 (2002).
200. Ito K, Sasano H, Yoshida Y, Sato S, Yajima A. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (CDK)2 and 4 in human endometrial carcinoma. Anticancer Res. 18(3A), 1661-1664 (1998).
201. Kato N, Watanabe J, Jobo T et al. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J. Cancer Res. Clin. Oncol. 129(4), 222-226 (2003).
202. Courjal F, Louason G, Speiser P et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer 69(4), 247-253 (1996).
203. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27(kip1), cyclin E and CDK2 expression in epithelial ovarian tumors. Gynecol. Oncol. 83(1), 56-63 (2001).
204. Farley J, Smith LM, Darcy KM et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a gynecologic oncology group study. Cancer Res. 63(6), 1235-1241 (2003).
205. Furihata M, Ohtsuki Y, Sonobe H et al. Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. Br. J. Cancer 77(5), 783-788 (1998).
206. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int. J. Cancer 102(6), 601-607 (2002).
207. Furihata M, Ohtsuki Y, Sonobe H et al. Cyclin A overexpression in carcinoma of the renal pelvis and ureter including dysplasia: immunohistochemical findings in relation to prognosis. Clin. Cancer Res. 3(8), 1399-1404 (1997).
208. Owa T, Yoshino H, Yoshimatsu K, Nagasu T Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. 8(12), 1487-1503 (2001).
209. Mendoza N, Fong S, Marsters J et al. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res. 63(5), 1020-1024 (2003).
210. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3(3), 233-245 (2003). Demonstrates for the first time that CDK2 activity is dispensable for colon cancer cell proliferation.
211. Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell 9(5), 931-943 (2002).
212. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. 153(3), 963-972 (1998).
213. Dobashi Y, Jiang SX, Shoji M, Morinaga S, Kameya T. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J. Pathol. 199(2), 208-220 (2003).
214. Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A and B, and prognosis in lymph node-negative breast cancer. J. Pathol. 199(4), 424-431 (2003).
215. Renshaw AA, Loughlin KR, Dutta A. Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod. Pathol. 11(10), 963-966. (1998).
216. Aaltomaa S, Lipponen P, Ala-Opas M et al. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br. J. Cancer 80(12), 2001-2007 (1999).
217. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Aberrant expression of cyclin A in laryngeal squamous cell carcinoma. Anticancer Res. 22(1A), 83-89 (2002).
218. Lotayef M, Wilson GD, Daley FM, Awwad HK, Shouman T. Aberrant expression of cyclin A in head and neck cancer. Br. J. Cancer 83(1), 30-34 (2000).
219. Miracco C, Pacenti L, Santopietro R et al. Detection of telomerase activity and correlation with mitotic and apoptotic indices, Ki-67 and expression of cyclins D1 and A in cutaneous melanoma. Int. J. Cancer 88(3), 411-416 (2000).
220. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J. Pathol. 195(5), 530-536 (2001).
221. Landberg G, Osdund H, Nielsen NH et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene 20(27), 3497-3505 (2001).
222. Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18(16), 2557-2566 (1999).
223. Donnellan R, Kleinschmidt I, Cherry R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum. Pathol. 32(1), 89-94 (2001).
224. Dosaka-Akita H, Hommura F, Mishina T et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res. 61(6), 2500-2504 (2001).
225. Takahashi S, Kamata Y, Tamo W et al. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int. J. Clin. Oncol. 7(6), 349-355 (2002).
226. Ferreri AJ, Ponzoni M, Pruneri G et al. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int. J. Cancer 94(4), 599-604 (2001).
227. Jung YJ, Lee KH, Choi DW et al. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett. 168(1), 57-63 (2001).
228. Cherry R, Sitti CW. Cyclin E immunoexpression in gastric cancer does not correlate with clinicopathological parameters. Histopathology 42(1), 66-69 (2003).
229. Jiaqing L, Hokita S, Xiangming C. Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer 1(2), 160-165 (1998).
230. Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int. J. Gynecol. Pathol. 22(2), 168-174 (2003).